================================================================================


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                  -------------

                                    FORM 8-K
                                  -------------

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


        Date of report (Date of earliest event reported): AUGUST 1, 2005



                         KERYX BIOPHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)





                                                
          DELAWARE                000-30929                   13-4087132
      (State or Other      (Commission File Number)  (IRS Employer Identification
        Jurisdiction                                             No.)
     of Incorporation)



                              750 LEXINGTON AVENUE
                            NEW YORK, NEW YORK 10022
                    (Address of Principal Executive Offices)

                                 (212) 531-5965
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]     Written communications pursuant to Rule 425 under the Securities Act.

[ ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

[ ]     Pre-commencement communications pursuant to Rule 14d-2b under the
        Exchange Act.

[ ]     Pre-commencement communications pursuant to Rule 13e-4(c) under the
        Exchange Act.

================================================================================

ITEM 2.02.  RESULTS OF OPERATIONS AND FINANCIAL CONDITION

      On August 1, 2005, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press
release announcing results of operations for the second quarter ended June 30,
2005. Keryx also announced that it would host a conference call on August 2,
2005, for investors where Keryx will discuss its results of operations and
financial results. A copy of such press release is being furnished as Exhibit
99.1 to this report.

                                   SIGNATURES


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                          KERYX BIOPHARMACEUTICALS, INC.
                                          (Registrant)



Date:  August 1, 2005

                                          By: /s/ Ron Bentsur
                                             ---------------------------
                                             Ron Bentsur
                                             Vice President Finance and
                                             Investor Relations

                                INDEX TO EXHIBITS




      EXHIBIT
      NUMBER            DESCRIPTION
      ------            -----------

                     
      99.1              Press Release dated August 1, 2005.